Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.

@article{Bohrmann2012GantenerumabAN,
  title={Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.},
  author={Bernd Bohrmann and Karlheinz Baumann and J. Benz and Francoise Gerber and Walter Huber and Fr{\'e}d{\'e}ric Knoflach and Juerg Messer and Krisztina Oroszlan and Robert Rauchenberger and Wolfgang Richter and Christine Rothe and Margit Urban and Michael Bardroff and Michael F. Winter and Christer Nordstedt and Hansruedi Loetscher},
  journal={Journal of Alzheimer's disease : JAD},
  year={2012},
  volume={28 1},
  pages={49-69}
}
The amyloid-β lowering capacity of anti-Aβ antibodies has been demonstrated in transgenic models of Alzheimer's disease (AD) and in AD patients. While the mechanism of immunotherapeutic amyloid-β removal is controversial, antibody-mediated sequestration of peripheral Aβ versus microglial phagocytic activity and disassembly of cerebral amyloid (or a… CONTINUE READING
  • Blog articles referencing this paper

  • Presentations referencing similar topics